Literature DB >> 33126384

The single nucleotide polymorphisms of interleukin-10 are associated with the risk of leukaemia: Evidence from 18 case-control studies.

Shupei Gao1, Kun Tang, Jinqing Chen, Jianmiao Wang.   

Abstract

Interleukin-10(IL-10) is an immunosuppressive cytokine and plays an important role in inflammation and cancers. Numerous studies have explored the association between single nucleotide polymorphisms of IL-10 and leukemia, but their results were conflicting, so we performed this meta-analysis to elucidate the association between 3 common single nucleotide polymorphisms of IL-10 (rs1800896, rs1800871 and rs1800872) and risk of leukemia.We conducted a comprehensive research in Pubmed, Chinese Biomedical Literature Database disc and Embase using related terms. After strict selection, 18 studies with 2264 cases and 3846 controls were included into this meta-analysis. Odds ratio and 95% confidence interval were used to evaluate the strength of the association.We found that polymorphism of IL-10 -1082A/G was associated with decreased risk of leukemia both in overall analysis and in stratified analysis according to ethnicity and cancer type. A strong relationship was also uncovered between polymorphism of IL-10 -592C/A and increased risk of leukemia in non-Chinese.GG genotype of IL-10 -1082A/G is associated with decreased risk of leukemia, especially chronic lymphocytic leukemia. CC genotype of -592C/A is associated with decreased risk of leukemia in non-Chinese.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33126384      PMCID: PMC7598852          DOI: 10.1097/MD.0000000000023006

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


Introduction

Leukemia is 1 of the commonest cancers across the world, with a top ten incidence and mortality in both sex and all ages.[ The incidence and mortality increased to the fifth place among children, adolescents and young adults.[ However, the mechanisms underlying leukemia are complex and not fully known. More and more researches revealed the indispensable participation of immunity during the process of cancers. Immunosuppressive cytokines such as interleukin-10 (IL-10) and transforming growth factor-β play important roles in the immunity of tumor.[ IL-10 belongs to Th2 pathway. It can counterbalance the immune system by regulating both adaptive and innate immune system to protect host from exacerbated inflammation.[ Altered expression of IL-10 may lose the control of immune homeostasis, thereby increasing the risk of cancers.[ Recent genetic studies disclosed the important role of single nucleotide polymorphisms (SNPs) in many kinds of cancers.[ SNPs in gene regulating and coding areas can alter the expression level or function of these gene or the products they encode. So SNPs are increasingly found to be critical in the mechanisms of cancers.[ SNPs in the transcriptional start area of IL-10 gene influence the production of IL-10 thus may increase or decrease the risk of cancers,[ including leukemia, but the conclusions are inconsistent. For example, Ovsepyan, V. A. et al[ found SNP in the IL-10 -1082A/G was associated with the risk of chronic lymphoid leukemia, while Lo, W. J. et al[ found no association between IL-10 -1082A/G and leukemia. Conflicting results may be due to small sample size. So we performed this pooled analysis to elucidate the relations between leukemia and 3 common SNPs of IL-10(-1082A/G, -819 C/T, -592C/A).

Material and method

Patient involvement and ethical approval

There was no patient involvement in this study. Ethical approval is not necessary for a meta-analysis.

Literature search and identification

We conducted a comprehensive search in Pubmed, Chinese Biomedical Literature Database disc, EMBASE with following related terms: (“IL-10” OR “IL10” OR “interleukin10” OR “rs1800896” OR “rs1800871 ” OR “rs1800872 ”) AND (“polymorphism∗” OR “variant∗” OR “gene∗” OR “variation∗” OR “SNP∗”) AND (“leukemia” OR “leukaemia”). All publications were updated to April 22, 2019. We included studies with inclusion criteria as follows: written in English or Chinese; human case-control studies about the association between leukemia and any 1 of the 3 SNPs mentioned above; available genotype data for estimation of an odds ratio (OR) and 95% confidence interval (CI). The exclusion criteria were: reviews, letters, editorial articles or case reports; without controls or genotype data. The latest study was adopted when overlapping with previous studies.

Data extract

Title and abstract of all articles were screened by 2 reviewers independently and eligible studies were identified according to the inclusion and exclusion criteria. Two investigators extracted data independently from selected studies. From each study, the following information was obtained: the first author's name, publication year, country where study was conducted, source of control, genotyping method, cancer type, and genotypes of cases and controls.

Statistics analysis

For each study, Pearson χ2 and P value were calculated to test whether the genotype frequencies in controls were consistent with Hardy-Weinberg equilibrium. We estimated odds ratio and 95% CI to assess the linkage between risk of leukemia and 3 SNPs under 4 comparisons (homozygote comparison, heterozygote comparison, dominant and recessive genetic model comparison). For IL-10 -1082A/G (rs1800896), they were GG vs AA, GA vs AA, GG+GA vs AA, GG vs GA+AA respectively. For IL-10 -819C/T (rs1800871), they were TT vs CC, TC vs CC, TT+TC vs CC, TT vs TC+CC. For IL-10 -592C/A (rs1800872), they were AA vs CC, AC vs CC, AA+AC vs CC, AA vs AC+CC. Subgroup analysis was conducted by ethnicity (Chinese or non-Chinese), phase (acute or chronic) and cancer type (acute myelocytic leukemia, acute lymphoblastic leukemia, chronic myelocytic leukemia and chronic lymphocytic leukemia [CLL]). Heterogeneity among studies was calculated using Q-statistics and I2 statistics. We thought there was no significant heterogeneity when P > 0.1 or I2 < 50%, then fixed-effects models were adopted, otherwise random-effects models were adopted.[ We also performed stratified analysis to figure out the cause of heterogeneity and to reduce it. Z-test was conducted to exam the significance of ORs and 2-sided P < .05 was considered significant. Sensitivity analysis was conducted by recalculating overall ORs after omitting each individual study in turn. We also used Begg funnel plot and Egger linear regression test to detect publication bias.[ All analysis was performed using Review Manager 5.0.23 (Cochrane Library Software, Oxford) and STATA14.0 software (STATA Corporation, College Station, Texas).

Results

Characteristics of studies

After searching on Pubmed, Chinese Biomedical Literature Database disc, and Embase using retrieval strategy mentioned above, 425 articles were recruited. 387 studies were excluded (107 duplicates, 280 studies unrelated), with 38 articles being left for full-text review. Next, 20 articles were removed for the following reasons: 5 articles were not case-control studies; 6 articles lack available data; 6 articles were not about the association between leukemia and SNPs of IL-10; 1 study studied other SNPs of IL-10; 1 article overlapped with another study; 1 article was written in Turkish. Finally, there were 18 studies with 2264 cases and 3846 controls included into this meta-analysis. The process of selecting included studies is shown in Figure 1.
Figure 1

Process of selecting included studies in this meta-analysis.

Process of selecting included studies in this meta-analysis. The details of eligible studies are presented in Table 1. Most studies were performed in non-Chinese ethnicity,[ with 4 studies in Chinese population.[ We found that controls in 6 studies were not consistent with Hardy-Weinberg equilibrium[ maybe because of genotyping error or selection bias during controls’ recruitment.
Table 1

Characteristics of published studies included in this meta-analysis.

Characteristics of published studies included in this meta-analysis.

Quantitative synthesis

The association between 3 SNPs of IL-10 and leukemia by overall analysis and subgroup analysis is shown in Table 2 and Table 3 . The overall analysis indicated that rs1800896 polymorphism was associated with risk of leukemia under recessive genetic model comparison (GG vs GA+AA: OR, 0.83; 95% CI, 0.83[0.71,0.98], P = .03, Fig. 2).
Table 2

Overall analysis of association between 3 SNPs of IL-10 and risk of leukaemia.

Table 3

Stratified analysis of association between 3 SNPs of IL-10 and risk of leukemia.

Figure 2

Overall analysis for the association between IL-10 rs1800896 polymorphism and leukemia risk (GG vs GA+AA).

Overall analysis of association between 3 SNPs of IL-10 and risk of leukaemia. Stratified analysis of association between 3 SNPs of IL-10 and risk of leukemia. Stratified analysis of association between 3 SNPs of IL-10 and risk of leukemia. Overall analysis for the association between IL-10 rs1800896 polymorphism and leukemia risk (GG vs GA+AA). Stratified analysis by ethnicity indicated that polymorphism of IL10 -1082 A/G(rs1800896) was associated with leukemia in non-Chinese under homozygote comparison and recessive genetic model comparison (GG vs AA: OR, 0.80; 95% CI, 0.80[0.66,0.97], P = .03; GG vs GA+AA: OR, 0.80; 95% CI, 0.80[0.67,0.95], P = .01). Besides, subgroup analysis of IL10 -1082 A/G by phase of leukemia indicated that GG genotype was associated with decreased risk of chronic leukemia (GG vs AA: OR, 0.74; 95% CI, 0.74[0.57,0.95], P = .02; GG vs GA+AA: OR, 0.78; 95% CI, 0.78[0.62,0.98], P = .03.), especially CLL, for stratified analysis by cancer type showed a strong link between this polymorphism and risk of CLL under homozygote comparison and recessive genetic model comparison (GG vs AA: OR, 0.74; 95% CI, 0.74[0.55,0.98], P = .04; GG vs GA+AA: OR, 0.77; 95% CI, 0.77[0.60,0.99], P = .04 Fig. 3).
Figure 3

Subgroup analyses for the association between IL-10 rs1800896 polymorphism and leukemia risk according to cancer type (GG vs GA+AA).

Subgroup analyses for the association between IL-10 rs1800896 polymorphism and leukemia risk according to cancer type (GG vs GA+AA). We found no association between IL-10 -819 C/T (rs1800871) and leukemia in overall analysis and subgroup analysis. We found no association between IL-10 -592C/A (rs1800872) and leukemia in overall analysis. But we found a strong association between rs1800872 and leukemia in non-Chinese under heterozygote comparison and dominant genetic model comparison. (AC vs CC: OR, 1.24; 95% CI, 1.24[1.02,1.50], P = .03, Fig. 4. AA+AC vs CC: OR,1.22; 95%CI,1.22[1.01,1.46], P = .04).
Figure 4

Subgroup analyses for the association between IL-10 rs1800872 polymorphism and leukemia risk according to ethnicity (AC vs CC).

Subgroup analyses for the association between IL-10 rs1800872 polymorphism and leukemia risk according to ethnicity (AC vs CC).

Test of heterogeneity

For the overall test of heterogeneity, most comparisons had low or moderate heterogeneity. The heterogeneity of rs1800896 was low or moderate(GG vs AA: P = .21, I2 = 22%; GA vs AA:P = .02, I2 = 48%; GG+GA vs AA:P = .006, I2 = 54%; GG vs GA+AA: P = .48, I2 = 0%.), while the heterogeneity of rs1800871(TT vs CC: P < .0001, I2 = 73%; TC vs CC: P = .0004, I = 66%; TT+TC vs CC:P < .0001, I = 69%; TT vs TC+CC: P < .00001, I2 = 79%.) and rs1800872(AA vs CC: P < .00001, I2 = 81%; AC vs CC:P = .003, I2 = 61%; AA+AC vs CC:P = .0001, I2 = 70%; AA vs AC+CC: P < .00001, I2 = 88%.) was moderate or high. In the subgroup analysis according to ethnicity, the heterogeneity of rs1800872 was moderate or high in Chinese (AA vs CC: P < .00001, I2 = 93%; AC vs CC:P = .04, I2 = 64%; AA+AC vs CC:P = .0002, I2 = 84%; AA vs AC+CC: P < .00001, I2 = 96%.) while low or moderate in non-Chinese(AA vs CC: P = .15, I2 = 35%; AC vs CC:P = .58, I2 = 0%; AA+AC vs CC:P = .45, I2 = 0%; AA vs AC+CC: P = .17, I2 = 33%.).

Sensitivity analysis

Sensitivity analysis was conducted by omitting each study in turn. There was no big change when omitting each article, indicating the result was stable and trustworthy. Figure 5 shows the sensitivity analysis for the association between polymorphism of rs1800896 and risk of leukemia under recessive genetic model comparison (GG vs GA+AA).
Figure 5

Sensitivity analysis for the association between polymorphism of rs1800896 and risk of leukemia under recessive genetic model comparison (GG vs GA+AA).

Sensitivity analysis for the association between polymorphism of rs1800896 and risk of leukemia under recessive genetic model comparison (GG vs GA+AA).

Publication bias

Figure 6 shows the Begg funnel plot for the association between polymorphism of rs1800871 and leukemia under heterozygote comparison (TC vs CC). There was no evidence of publication bias both in Begg funnel plots and Egger test. The symmetry of the Begg funnel plot was good and P values for Begg tests and Egger tests were >0.05. Begg funnel plots for the association between polymorphism of rs1800871 and leukemia under homozygote comparison (TT vs CC) in non-Chinese are shown in Figure 7. These data indicated that there was no significant publication bias in this meta-analysis.
Figure 6

Begg funnel plot for publication bias of overall analysis for the association between polymorphism of rs1800871 and leukemia (TC vs CC; P for bias = .951).

Figure 7

Begg funnel plot for publication bias of stratified analysis for the association between polymorphism of rs1800871 and leukemia in non-Chinese (TT vs CC; P for bias = .076).

Begg funnel plot for publication bias of overall analysis for the association between polymorphism of rs1800871 and leukemia (TC vs CC; P for bias = .951). Begg funnel plot for publication bias of stratified analysis for the association between polymorphism of rs1800871 and leukemia in non-Chinese (TT vs CC; P for bias = .076).

Discussion

More and more researches concentrate on immunity when exploring the etiology of cancers. IL-10 plays a suppressive role on many types of cells in general,[ but it has pleiotropic functions on tumor. IL-10 can impose both stimulatory and inhibitory impact on T cells.[ There are studies revealing that IL-10 can fight against tumor by activating CD8+ T cells and cause the accumulation of tumor infiltrating lymphocytes (TILs),[ while others indicate that IL-10 can promote the development and progression of tumors.[ It has been reported that polymorphisms in the promoter region of IL-10 may influence the production of IL-10.[ There are many studies and systematic analyses reporting the association between SNPs of IL-10 and other cancers, including gastric cancer40,[ cervical cancer,[ breast cancer,[ and prostate cancer.[ Recently, numerous studies focus on the association of SNPs in the promoter of IL-10 (such as rs1800896, rs1800871 and rs1800872) and risk of leukemia, but their results are conflicting. There is 1 pooled analysis involving 4 studies found that there was no association between SNP of IL-10 and CLL,[ but it only surveyed 1 SNP of IL-10, rs1800896. Besides, it only focused on CLL, ignoring the other 3 kinds of leukemia. In addition, it only took 4 studies into analysis. So we conducted this meta-analysis involving 18 articles with 2264 cases and 3846 controls to illuminate the link between 3 common SNPs of IL-10 and leukemia. In the overall analysis, we found a strong association between polymorphism of rs1800896 and leukemia under recessive genetic model comparison (GG vs GA+AA) which means GG genotype of rs1800896 was associated with decreased risk of leukemia in overall population. However, rs1800871 and rs1800872 exerted no impact on the susceptibility to leukemia in overall analysis. In the subgroup analysis according to ethnicity, a strong association was found between rs1800896 and leukemia in non-Chinese under homozygote comparison (GG vs AA) and recessive genetic model comparison (GG vs GA+AA) while the result was negative in Chinese under the same comparison. So in non-Chinese, individuals with GG genotype of rs1800896 may have lower risk of leukemia when compared with those carrying GA or AA genotype. When stratified by cancer types, we found GG genotype of rs1800896 was associated with decreased risk of chronic leukemia, especially CLL under homozygote comparison (GG vs AA) and recessive genetic model comparison (GG vs GA+AA). However, no association was found between rs1800871 and leukemia when stratified by ethnicity and cancer type. Stratified analysis by ethnicity has effectively minimized the heterogeneity. Heterogeneity was low or moderate in non-Chinese while moderate or high in Chinese, maybe because types of leukemia were different in these 4 Chinese studies (2 of them were acute myelocytic leukemia and the other 2 were acute lymphoblastic leukemia) or patients with different comorbidities were recruited or caused by other statistic or methodological reasons, so we adopted random-effects model. Under random-effects model, rs1800872 was associated with leukemia risk in non-Chinese under heterozygote comparison (AC vs CC) and dominant genetic model comparison (AA+AC vs CC), which means in non-Chinese, individuals with AA or AC genotype may have increased risk of leukemia. As for Chinese group, perhaps there was no significant association between rs1800872 and leukemia. No association was found when stratified by cancer type. The fact that heterogeneities of some comparisons were high cannot be ignored. Although we have carried out a careful research when searching articles, selected eligible studies strictly following inclusion and exclusion criterion, paid attention to every process of this analysis, some comparisons still had high heterogeneity. Heterogeneity was effectively minimized after stratified analysis, but significant heterogeneity still existed in some comparisons, maybe because of different source of control (controls of some studies are hospital-based), different genotyping methods, sample error or other unidentified reasons. There was no evidence of publication bias both in Begg funnel plot and Egger test. There are several limitations of this meta-analysis. Firstly, we did not perform a stratified analysis according to sex or age because of lacking relevant original data. Secondly, the number of studies about the association between rs1800871 or rs1800872 and CLL is too small, including only 1 original article. Thirdly, Chinese studies about the association between rs1800896 and leukemia are limited, including only 2 studies. More studies are needed. Lastly, we only took articles written in English or Chinese into analysis, which may produce unavoidable bias.

Conclusions

In conclusion, this meta-analysis indicated that GG genotype of rs1800896 was associated with decreased risk of leukemia when compared with GA + AA. Strong association was found between GG genotype of rs1800896 and decreased risk of leukemia in non-Chinese compared with AA or GA + AA. In addition, GG genotype of rs1800896 was associated with decreased risk of chronic leukemia, especially CLL compared with AA or GA + AA. Lastly, we found CC genotype of rs1800872 was associated with decreased risk of leukemia in non-Chinese compared with AA or AA + AC.

Acknowledgments

We are thankful to all participants of our study.

Author contributions

SG searched literature, selected eligible studies, extracted and analysed data and drafted manuscript. KT and JC participated in article selection and data extraction. JW supervised literature search, data extraction, data analysis and drafted manuscript.
Table 3 (Continued)

Stratified analysis of association between 3 SNPs of IL-10 and risk of leukemia.

  42 in total

1.  Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk.

Authors:  A Nieters; L Beckmann; E Deeg; N Becker
Journal:  Genes Immun       Date:  2006-09-14       Impact factor: 2.676

2.  Synopsis and synthesis of candidate-gene association studies in chronic lymphocytic leukemia: the CUMAGAS-CLL information system.

Authors:  Elias Zintzaras; George D Kitsios
Journal:  Am J Epidemiol       Date:  2009-08-21       Impact factor: 4.897

3.  Bias in meta-analysis detected by a simple, graphical test.

Authors:  M Egger; G Davey Smith; M Schneider; C Minder
Journal:  BMJ       Date:  1997-09-13

4.  The Associations of IL-6, IFN-γ, TNF-α, IL-10, and TGF-β1 Functional Variants with Acute Myeloid Leukemia in Turkish Patients.

Authors:  Ayse Feyda Nursal; Mustafa Pehlivan; Handan Haydaroğlu Sahin; Sacide Pehlivan
Journal:  Genet Test Mol Biomarkers       Date:  2016-08-03

5.  Cytokine gene polymorphism in Iranian patients with chronic myelogenous leukaemia.

Authors:  A A Amirzargar; M Bagheri; A Ghavamzadeh; K Alimoghadam; F Khosravi; N Rezaei; M Moheydin; B Ansaripour; B Moradi; B Nikbin
Journal:  Int J Immunogenet       Date:  2005-06       Impact factor: 1.466

6.  Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation.

Authors:  C Andrew Stewart; Hannah Metheny; Noriho Iida; Loretta Smith; Miranda Hanson; Folkert Steinhagen; Robert M Leighty; Axel Roers; Christopher L Karp; Werner Müller; Giorgio Trinchieri
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

7.  Cytokine gene polymorphisms influence mucosal cytokine expression, gastric inflammation, and host specific colonisation during Helicobacter pylori infection.

Authors:  R Rad; A Dossumbekova; B Neu; R Lang; S Bauer; D Saur; M Gerhard; C Prinz
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

Review 8.  Cancer immunotherapy by dendritic cells.

Authors:  Cornelis J M Melief
Journal:  Immunity       Date:  2008-09-19       Impact factor: 31.745

9.  Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression.

Authors:  Yu Wang; Sheng-Nan Sun; Qing Liu; Yang-Yang Yu; Jian Guo; Kun Wang; Bao-Cai Xing; Qing-Feng Zheng; Michael J Campa; Edward F Patz; Shi-You Li; You-Wen He
Journal:  Cancer Discov       Date:  2016-06-13       Impact factor: 39.397

10.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study.

Authors:  Christina Fitzmaurice; Christine Allen; Ryan M Barber; Lars Barregard; Zulfiqar A Bhutta; Hermann Brenner; Daniel J Dicker; Odgerel Chimed-Orchir; Rakhi Dandona; Lalit Dandona; Tom Fleming; Mohammad H Forouzanfar; Jamie Hancock; Roderick J Hay; Rachel Hunter-Merrill; Chantal Huynh; H Dean Hosgood; Catherine O Johnson; Jost B Jonas; Jagdish Khubchandani; G Anil Kumar; Michael Kutz; Qing Lan; Heidi J Larson; Xiaofeng Liang; Stephen S Lim; Alan D Lopez; Michael F MacIntyre; Laurie Marczak; Neal Marquez; Ali H Mokdad; Christine Pinho; Farshad Pourmalek; Joshua A Salomon; Juan Ramon Sanabria; Logan Sandar; Benn Sartorius; Stephen M Schwartz; Katya A Shackelford; Kenji Shibuya; Jeff Stanaway; Caitlyn Steiner; Jiandong Sun; Ken Takahashi; Stein Emil Vollset; Theo Vos; Joseph A Wagner; Haidong Wang; Ronny Westerman; Hajo Zeeb; Leo Zoeckler; Foad Abd-Allah; Muktar Beshir Ahmed; Samer Alabed; Noore K Alam; Saleh Fahed Aldhahri; Girma Alem; Mulubirhan Assefa Alemayohu; Raghib Ali; Rajaa Al-Raddadi; Azmeraw Amare; Yaw Amoako; Al Artaman; Hamid Asayesh; Niguse Atnafu; Ashish Awasthi; Huda Ba Saleem; Aleksandra Barac; Neeraj Bedi; Isabela Bensenor; Adugnaw Berhane; Eduardo Bernabé; Balem Betsu; Agnes Binagwaho; Dube Boneya; Ismael Campos-Nonato; Carlos Castañeda-Orjuela; Ferrán Catalá-López; Peggy Chiang; Chioma Chibueze; Abdulaal Chitheer; Jee-Young Choi; Benjamin Cowie; Solomon Damtew; José das Neves; Suhojit Dey; Samath Dharmaratne; Preet Dhillon; Eric Ding; Tim Driscoll; Donatus Ekwueme; Aman Yesuf Endries; Maryam Farvid; Farshad Farzadfar; Joao Fernandes; Florian Fischer; Tsegaye Tewelde G/Hiwot; Alemseged Gebru; Sameer Gopalani; Alemayehu Hailu; Masako Horino; Nobuyuki Horita; Abdullatif Husseini; Inge Huybrechts; Manami Inoue; Farhad Islami; Mihajlo Jakovljevic; Spencer James; Mehdi Javanbakht; Sun Ha Jee; Amir Kasaeian; Muktar Sano Kedir; Yousef S Khader; Young-Ho Khang; Daniel Kim; James Leigh; Shai Linn; Raimundas Lunevicius; Hassan Magdy Abd El Razek; Reza Malekzadeh; Deborah Carvalho Malta; Wagner Marcenes; Desalegn Markos; Yohannes A Melaku; Kidanu G Meles; Walter Mendoza; Desalegn Tadese Mengiste; Tuomo J Meretoja; Ted R Miller; Karzan Abdulmuhsin Mohammad; Alireza Mohammadi; Shafiu Mohammed; Maziar Moradi-Lakeh; Gabriele Nagel; Devina Nand; Quyen Le Nguyen; Sandra Nolte; Felix A Ogbo; Kelechi E Oladimeji; Eyal Oren; Mahesh Pa; Eun-Kee Park; David M Pereira; Dietrich Plass; Mostafa Qorbani; Amir Radfar; Anwar Rafay; Mahfuzar Rahman; Saleem M Rana; Kjetil Søreide; Maheswar Satpathy; Monika Sawhney; Sadaf G Sepanlou; Masood Ali Shaikh; Jun She; Ivy Shiue; Hirbo Roba Shore; Mark G Shrime; Samuel So; Samir Soneji; Vasiliki Stathopoulou; Konstantinos Stroumpoulis; Muawiyyah Babale Sufiyan; Bryan L Sykes; Rafael Tabarés-Seisdedos; Fentaw Tadese; Bemnet Amare Tedla; Gizachew Assefa Tessema; J S Thakur; Bach Xuan Tran; Kingsley Nnanna Ukwaja; Benjamin S Chudi Uzochukwu; Vasiliy Victorovich Vlassov; Elisabete Weiderpass; Mamo Wubshet Terefe; Henock Gebremedhin Yebyo; Hassen Hamid Yimam; Naohiro Yonemoto; Mustafa Z Younis; Chuanhua Yu; Zoubida Zaidi; Maysaa El Sayed Zaki; Zerihun Menlkalew Zenebe; Christopher J L Murray; Mohsen Naghavi
Journal:  JAMA Oncol       Date:  2017-04-01       Impact factor: 31.777

View more
  1 in total

1.  IL-10 rs1800896 Polymorphism: A Risk Factor for Adult Acute Lymphoblastic Leukemia.

Authors:  Ezeldine K Abdalhabib; Badr Alzahrani; Muhammad Saboor; Alneil Hamza; Elyasa M Elfaki; Fehaid Alanazi; Fawaz O Alenazy; Abdulrahman Algarni; Ibrahim Khider Ibrahim; Hozifa A Mohamed; Ayman Hussein Alfeel; Nahla Ali Alshaikh
Journal:  Pharmgenomics Pers Med       Date:  2022-09-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.